Investigational drug · Phase 2
YL-13027
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Metastatic Pancreatic Cancer.
Phase 2Last checked: Nov 20, 2026Latest source record: Oct 29, 2024 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "YL-13027"
First trial start
2024
Nov 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YL-13027", any sponsor or status.
Conditions studied
As listed on its trial records.
- Metastatic Pancreatic Cancer
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "YL-13027" as an intervention, largest first.
- YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic CancerPivotal-lookingNot yet recruiting
Shanghai YingLi Pharmaceutical Co. Ltd.Industry
NCT06662669 · 120 participants (planned) · Start Nov 30, 2024 · Primary completion Sep 30, 2027
Drug: YL-13027; HY-0102 and 2 more · For: Metastatic Pancreatic Cancer
- YL-13027 in Patients With Advanced Solid TumorsStatus unknown
Shanghai YingLi Pharmaceutical Co. Ltd.Industry
NCT05228600 · 54 participants (planned) · Start May 17, 2022 · Primary completion Dec 30, 2022
Drug: YL-13027 · For: Solid Tumor
Sites: Houston, Texas
- A Phase 1b/2 Study of YL-13027 Combined With Sintilimab in Patients With Advanced Solid TumorsStatus unknown
Shanghai YingLi Pharmaceutical Co. Ltd.Industry
NCT05457517 · 49 participants (planned) · Start Sep 24, 2022 · Primary completion Jun 1, 2024
Drug: YL-13027,Sintilimab · For: Advanced Solid Tumors
Sites: Shanghai, China
- First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid TumorsStatus unknown
Shanghai YingLi Pharmaceutical Co. Ltd.Industry
NCT03869632 · 36 participants (planned) · Start Mar 19, 2019 · Primary completion Apr 30, 2021
Drug: YL-13027 · For: Advanced Solid Tumors
Sites: Shanghai, China
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT06199466 · 4 participants · Start Jan 22, 2024 · Primary completion Sep 15, 2025
Drug: Gemcitabine; Nab-paclitaxel and 1 more · For: Metastatic Pancreatic Cancer
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Single-cell transcriptome reveals cellular hierarchies and guides p-EMT-targeted trial in skull base chordoma.
Zhang Q, Fei L, Han R, et al. · Cell Discov 2022
Also in development for Metastatic Pancreatic Cancer
- YL201Tambotatug Pelitecan, Tam-PeliPhase 311 trials
MediLink Therapeutics (Suzhou) Co., Ltd. · Advanced Solid Tumor, Small Cell Lung Cancer, Metastatic Pancreatic Cancer
- CamrelizumabSHR-1210, CAMPhase 39 trials
Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- SetidegrasibASP3082Phase 32 trials
Astellas · Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma
- SurufatinibPhase 31 trial
Hutchmed · Metastatic Pancreatic Cancer
- BalstilimabAGEN2034Phase 23 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- Olaptesed pegolNOX-A12Phase 22 trials
TME Pharma AG · Metastatic Pancreatic Cancer, Glioblastoma
- ZalifrelimabPhase 22 trials
ImmunoGenesis · Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
- HY-0102Phase 21 trial
Shanghai YingLi Pharmaceutical Co. Ltd. · Metastatic Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.